Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
05 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
02 oct. 2023 04h00 HE
|
Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Dyadic to Present at Industry and Investor Events in October
29 sept. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October
Infectious Disease Diagnostics Market to Hit $37.94 Billion, Globally, by 2028 – Exclusive Report by The Insight Partners
20 sept. 2023 10h22 HE
|
The Insight Partners
Pune, India., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tuberculosis (TB) is the 13th most significant cause of mortality globally and the second leading infectious disease after COVID-19, according to the...
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
20 juil. 2023 08h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
LEX Diagnostics Appoints Chief Technology Officer
18 juil. 2023 03h00 HE
|
LEX Diagnostics
CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- LEX Diagnostics (LEX) today announces the appointment of Dr Heather Danks as its Chief Technology Officer (CTO). The company is...
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
21 juin 2023 08h33 HE
|
Dyadic International, Inc.
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Influenza Vaccines Market Size to Surpass USD 11.7 Billion by 2030 at 6.53% CAGR – Report by Market Research Future (MRFR)
29 mai 2023 09h30 HE
|
Market Research Future
New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Influenza Vaccines Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Influenza Vaccines Market...
Dyadic to Participate at Two Industry Events in May
10 mai 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
18 avr. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...